Share on StockTwits

CombiMatrix (NASDAQ:CBMX) CEO Mark D. Mcdonough acquired 12,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 27th. The shares were purchased at an average price of $2.02 per share, with a total value of $24,240.00. Following the completion of the purchase, the chief executive officer now directly owns 13,500 shares in the company, valued at approximately $27,270. The purchase was disclosed in a document filed with the SEC, which is available at this link.

CombiMatrix (NASDAQ:CBMX) traded down 3.90% during mid-day trading on Thursday, hitting $1.97. 167,693 shares of the company’s stock traded hands. CombiMatrix has a 1-year low of $1.91 and a 1-year high of $4.44. The stock’s 50-day moving average is $2.16 and its 200-day moving average is $2.49. The company’s market cap is $21.8 million.

Separately, analysts at Zacks reiterated an “outperform” rating on shares of CombiMatrix in a research note on Friday, August 8th. They now have a $3.50 price target on the stock.

CombiMatrix Corporation is a molecular diagnostics company. The Company operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc located in Irvine, California.

Receive News & Ratings for CombiMatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix and related companies with Analyst Ratings Network's FREE daily email newsletter.